Benzydamine and inflammatory pain – Molecular Pain

A new article was released in Molecular Pain magazine, in which our estimated colleague Giorgina Mangano is one of the authors!

Benzydamine, an active pharmaceutical compound, was shown to have analgesic and anaesthetic properties after local applications. The chemical is generally used in oral care pharmaceutical preparations due to its anti-inflammatory actions, acting on pro-inflammatory mediators’ synthesis and release. Moreover, benzydamine seems to have a role as neuronal excitability modulator, which still needs to be fully explored.

With this aim, the research group studied the effect of benzydamine over the excitability of primary cultured DRG nociceptors and after acute and chronic inflammatory sensitization, as a model to evaluate relative nociceptive response.

The chemical demonstrated to effectively inhibit neuronal basal excitability, reducing its firing frequency and increasing rheobase and afterhyperpolarization amplitude in a dose-dependent manner. in particular, high doses of benzydamine induced changes in action potential wavelength, decreasing its height and slightly increasing its duration. Additionally, it inhibited neuronal excitability mediated either by an inflammatory cocktail, acidic pH or high external KCl, with higher potency under inflammatory sensitized conditions.
This effect could be attributed to the modulation of inflammatory and neuronal sensitizing signaling pathways or the direct regulation of proalgesic and action potential-initiating ion channels. Notably, the compound demonstrated inhibition of the Nav1.8 channel while showing no impact on Kv7.2, Kv7.3, TRPV1, and TRPA1 channels.

To gain further insight in this research project, check the full paper, which is freely available online!
Click here for a quick redirection.

Reference:

Nikolaeva-Koleva M, Espinosa A, Vergassola M, Polenzani L, Mangano G, Ragni L, Zucchi S, Ferrer-Montiel A, Devesa I. Benzydamine plays a role in limiting inflammatory pain induced by neuronal sensitization. Mol Pain. 2023 Jan-Dec;19:17448069231204191. doi: 10.1177/17448069231204191. PMID: 37710969; PMCID: PMC10583526.